Neil Kumar, Ph.D., serves on the PellePharm board of directors.
Neil is the chief executive officer of Eidos Therapeutics and chief executive officer and co-founder of its parent company, BridgeBio Pharma. Prior to founding BridgeBio, he was a principal at Third Rock Ventures, where he supported and managed various portfolio companies and focused on new company formation and due diligence. Neil also served as interim vice president of business development and operations for MyoKardiam, Inc., a precision medicine company working on targeted therapies for the treatment of rare cardiovascular diseases. Previously, Neil served as an associate principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies and helped lead personalized medicine efforts. Neil was also involved in the formation of a gene chip company and was a technical consultant for AstraZeneca’s pathway signaling group.
Neil earned his Ph.D. in chemical engineering from the Massachusetts Institute of Technology and holds bachelor’s and master’s degrees in chemical engineering from Stanford University. He is the author of several peer-reviewed papers in the fields of oncology and systems biology.